T-3011 is under clinical development by Immvira and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how T-3011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
T-3011 is under development for the treatment of advanced malignancy, solid tumors such as metastatic melanoma, hepatocellular carcinoma, colorectal cancer, ovarian cancer, lung cancer, liver cancer, lymphoma, malignant pleural mesothelioma, breast cancer, sarcomas, lung cancer, head and neck squamous-cell carcinoma, cutaneous squamous cell carcinoma (cSCC), esophageal cancer and non-small cell lung cancer, pancreatic cancer, colon cancer and endometrial cancer and malignant glioma. The drug candidate is a re-targeted next generation herpes simplex virus (oncolytic virus) encoding PD-1 antibody and interleukin 12 (IL12) gene. It is administered through intratumoral and intravenous route.
Immvira is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, which not only improves the replicating ability of the virus but also further improves the oncolytic activity of the virus and promotes the immune response. The company is headquartered in Shenzhen, Guangdong, China.
For a complete picture of T-3011’s drug-specific PTSR and LoA scores, buy the report here.